Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14094818 | 1.00 | HPGD (0.59) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL3568567 | 0.85 | HPGD (0.63) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL8487833 | 0.84 | SMN1; SMN2 (0.59) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11788057 | 0.84 | SMN1; SMN2 (0.59) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL229498 | 0.83 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL1300333 | 0.83 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL566636 | 0.83 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL1567597 | 0.83 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL2977327 | 0.83 | NISCH (0.71) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL30946854 | 0.83 | NISCH (0.71) | HPGDALDH1A1SMN1; SMN2NISCHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230736-A1 | ENGINEERED BIOCATALYSTS FOR THE SYNTHESIS OF GAMMA-HYDROXY AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-2713736-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2017-08-10 | — | — | US | disclosed |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2017-08-10 | — | — | US | disclosed |
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-9637489-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637489-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-4217305-A | HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | HPGD 610/4885ALDH1A1 1121/4885SMN1; SMN2 4517/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | HPGD 3839/4885ALDH1A1 2843/4885SMN1; SMN2 848/4885 |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | TACR1, NPSR1, TACR2 | HPGD 1462/4885ALDH1A1 1817/4885SMN1; SMN2 4061/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | HPGD 1358/4885ALDH1A1 904/4885SMN1; SMN2 2313/4885 |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | HPGD 2582/4885ALDH1A1 2143/4885SMN1; SMN2 1105/4885 |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TLR7, C5, CD4 | HPGD 2227/4885ALDH1A1 4537/4885SMN1; SMN2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.